ReviewOxidative medicine and cellular longevity2017

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.

Seraina Faes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.